Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Human Papillomavirus Genotypes Associated with Mucopurulent Cervicitis and Cervical Cancer in Hangzhou, China

  • Shen, Xing-Hang (Department of Obstetrics and Gynecology, Chinese Medicine Hospital of Hangzhou) ;
  • Liu, Shu-Hua (Department of Obstetrics and Gynecology, Chinese Medicine Hospital of Hangzhou)
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: To investigate the infection status and predominant genotype distribution of human papillomavirus (HPV) infection among Chinese patients with mucopurulent cervicitis (MPC) or cervical cancer (CC) in Hangzhou. Methods: Initially, 217 cases of healthy cervix controls (n=50), acute MPC (n=89), and CC (n=78) were included; samples were collected between January 1, 2010, and January 30, 2013. Cervical specimens were screened for HPV using a nested polymerase chain reaction assay and DNA sequencing. Results: Overall prevalence of HPV infection was 16.7% in the control group, 51.9% in the MPC group, and 84.4% in the CC group. The predominant genotype detected in all 3 groups was the oncogenic variant HPV 16 (55.8%, 17.3%, and 6.3% in the CC, MPC and control specimens, respectively), HPV58 was the second most predominant HPV type in CC (9.1%), MPC (8.6%), and control group (4.2%). Most or all of the genotypes were oncogenic in the three groups. Conclusions: Infection with HPV was found to be prevalent among Chinese women with MPC or CC and oncogenic variants were in the majority. Therefore, peoples who suffered MPC with HPV DNA positive should be regularly followed-up, for prevention and early treatment of cervical cancer.

Keywords

References

  1. Altuglu I, Terek MC, Ozacar T, et al (2002). The prevalence of human papilloma virus DNA in women with mucopurulent endocervicitis. Eur J Gynecol Oncol, 23, 166-8.
  2. Bao YP, Li N, Smith JS, et al (2008a). Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer, 18, 71-9.
  3. Bao YP, Li N, Smith JS, et al (2008b). YL. Human papillomavirus type-distribution in the cervix of Chinese women: a metaanalysis. Int J STD AIDS, 19, 106-11. https://doi.org/10.1258/ijsa.2007.007113
  4. Bosch FX, Lorincz A, Munoz N, et al (2002). The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 55, 244-65. https://doi.org/10.1136/jcp.55.4.244
  5. Cai YP, Yang Y, Zhu BL, et al (2013). Zhang RF, Xiang Y. Comparison of human papillomavirus detection and genotyping with four different prime sets by PCRsequencing. Biomed Environ Sci, 26, 40-7.
  6. Ghosh SK, Choudhury B, Hansa J (2011). Human papillomavirus testing for suspected cervical cancer patients from Southern Assam by fast-PCR. Asian Pac J Cancer Prev, 12, 749-51.
  7. Paavonen J, Critchlow CW, Rouen T, et al (1986). Etiology of cervical inflammation. Am J Obstet Gynecol, 154, 556-64. https://doi.org/10.1016/0002-9378(86)90601-0
  8. Poljak M, Kocjan BJ (2010). Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther, 8, 1139-62. https://doi.org/10.1586/eri.10.104
  9. Liu Y, Zhang L, Chen Y, et al (2011). HPV infection in 1088 gynecological patients in Zhejiang province. Chin J Clin Infect Dis[Article in Chinese] , 4, 106-8.
  10. Liu W, Wu EQ, Yu XH, et al (2013). Detection of human papillomavirus genotypes associated with mucopurulent cervicitis and cervical cancer in Changchun, China. Int J Gynaecol Obstet, 120, 124-6. https://doi.org/10.1016/j.ijgo.2012.07.032
  11. Lo KW, Wong YF, Chan MK, et al (2002). Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer, 100, 327-31. https://doi.org/10.1002/ijc.10506
  12. Qiao YL, Sellors JW, Eder PS, et al (2008). A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol, 9, 929-36. https://doi.org/10.1016/S1470-2045(08)70210-9
  13. Walboomers JM, Jacobs MV, Manos MM, et al (1999).Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  14. Willmott FE (1988). Mucopurulent cervicitis: a clinical entity? Genitourin Med, 64, 169-71.
  15. Zhang EY, Tang XD (2012). Human papillomavirus type 16/18 oncoproteins: potential therapeutic targets in non-smoking associated lung cancer. Asian Pac J Cancer Prev, 13, 5363-9. https://doi.org/10.7314/APJCP.2012.13.11.5363

Cited by

  1. MicroRNA-101 Inhibits Cell Proliferation, Invasion, and Promotes Apoptosis by Regulating Cyclooxygenase-2 in Hela Cervical Carcinoma Cells vol.14, pp.10, 2013, https://doi.org/10.7314/APJCP.2013.14.10.5915
  2. Polymorphisms and Functional Analysis of the Intact Human Papillomavirus16 E2 Gene vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10255
  3. Type-Specific Human Papillomavirus Distribution in Invasive Squamous Cervical Carcinomas in Tunisia and Vaccine Impact vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6769
  4. Efficacy and safety of combined high-dose interferon and red light therapy for the treatment of human papillomavirus and associated vaginitis and cervicitis vol.97, pp.37, 2018, https://doi.org/10.1097/MD.0000000000012398